An FDA review of data from the ACCORD Lipid trial found no significant difference in the risk of major cardiovascular events between type 2 diabetes patients treated with Abbott Laboratories' cholesterol-lowering drug Trilipix plus simvastatin and those given only simvastatin. The finding prompted the FDA to issue a safety alert and update prescribing information for Trilipix. The agency also asked Abbott to conduct a trial looking at the medication's cardiovascular effects on statin users.

Related Summaries